It also operates a European based product development division. Although Amarin is domiciled in the UK, its main operation is in the US and its primary listing is on Nasdaq. Emerging Specialist Pharmaceutical Company Amarin has been comprehensively restructured over the last two years. It changed its name in 1999 to reflect the change in strategy to specialty pharmaceuticals. Amarin currently markets and sells U.S. brand name prescription and OTC drugs to high prescribing primary care and select specialty physicians through direct marketing activities.
Manufacture is outsourced.
Amarin also develops drug delivery formulations under contract for third parties. Amarin's main business group is Amarin Pharmaceuticals, the US marketing company, based in New Jersey. A key part of Amarin's strategy is to acquire licences for pharmaceutical products that larger companies do not actively market increasing sales through aggressive promotional activities. All have US approval but had not been actively promoted for some time before acquisition by Amarin. The company believes that revenues for these products are capable of significant expansion.